Post-Operative Pain - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H1 2015', provides an overview of the Post-Operative Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Post-Operative Pain Overview 11 Therapeutics Development 12 Pipeline Products for Post-Operative Pain - Overview 12 Pipeline Products for Post-Operative Pain - Comparative Analysis 13 Post-Operative Pain - Therapeutics under Development by Companies 14 Post-Operative Pain - Therapeutics under Investigation by Universities/Institutes 17 Post-Operative Pain - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Post-Operative Pain - Products under Development by Companies 21 Post-Operative Pain - Products under Investigation by Universities/Institutes 23 Post-Operative Pain - Companies Involved in Therapeutics Development 24 A. Menarini Industrie Farmaceutiche Riunite Srl 24 AcelRx Pharmaceuticals, Inc. 25 Adynxx, Inc. 26 AngioChem Inc. 27 Boehringer Ingelheim GmbH 28 Cara Therapeutics, Inc. 29 Chong Kun Dang Pharmaceutical Corp. 30 Cytogel Pharma, LLC 31 DURECT Corporation 32 Echo Pharmaceuticals B.V. 33 Encore Therapeutics Inc. 34 Flexion Therapeutics, Inc. 35 Galleon Pharmaceuticals 36 Grunenthal GmbH 37 GW Pharmaceuticals plc 38 Heron Therapeutics, Inc. 39 Immupharma Plc 40 INSYS Therapeutics, Inc. 41 Laboratorios Del Dr. Esteve S.A. 42 Medtronic, Inc. 43 Ocular Therapeutix, Inc. 44 Omeros Corporation 45 Orbis Biosciences, Inc. 46 Orion Oyj 47 Pharmazz, Inc. 48 PhytoHealth Corporation 49 Recro Pharma, Inc. 50 Rottapharm SpA 51 Takeda Pharmaceutical Company Limited 52 Thar Pharmaceuticals, Inc. 53 Trevena, Inc. 54 UMeWorld Limited 55 Post-Operative Pain - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Combination Products 57 Assessment by Target 58 Assessment by Mechanism of Action 60 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 (bupivacaine hydrochloride + meloxicam) - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 (dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 (ketoprofen + amitriptyline + oxymetazoline) - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 (ketorolac tromethamine + phenylephrine hydrochloride) - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 AM-4 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ANG-2002 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ARX-01 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ARX-8028 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 ARX-8203 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 AYX-1 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 BI-1026706 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 bupivacaine hydrochloride - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 bupivacaine hydrochloride liposomal - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 bupivacaine hydrochloride SR - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 buprenorphine hydrochloride - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 centhaquine - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 CKD-943 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 CMX-020 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 CR-4056 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 CR-845 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Cyt-1010 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 dexamethasone acetate SR - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 dexmedetomidine hydrochloride - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 dronabinol - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 E-52862 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 fadolmidine hydrochloride - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 FX-007 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 GAL-044 - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 GIBH-1014 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 grapiprant - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 IPP-102199 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 ketamine hydrochloride ER - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 MDT-10013 - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 nabiximols - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 nalbuphine hydrochloride - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 ropivacaine - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 ropivacaine ER - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 T-109 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 tapentadol hydrochloride - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 tramadol hydrochloride - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 TRV-130 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 VVZ-149 - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 Post-Operative Pain - Recent Pipeline Updates 126 Post-Operative Pain - Dormant Projects 153 Post-Operative Pain - Discontinued Products 155 Post-Operative Pain - Product Development Milestones 156 Featured News & Press Releases 156 Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain 156 Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS 158 Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain 158 Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain 159 Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130 159 Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN 159 Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain 160 May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program 161 May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 161 May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 162 Appendix 164 Methodology 164 Coverage 164 Secondary Research 164 Primary Research 164 Expert Panel Validation 164 Contact Us 165 Disclaimer 165
List of Tables Number of Products under Development for Post-Operative Pain, H1 2015 12 Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2015 23 Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 24 Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015 25 Post-Operative Pain - Pipeline by Adynxx, Inc., H1 2015 26 Post-Operative Pain - Pipeline by AngioChem Inc., H1 2015 27 Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2015 28 Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H1 2015 29 Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 30 Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H1 2015 31 Post-Operative Pain - Pipeline by DURECT Corporation, H1 2015 32 Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2015 33 Post-Operative Pain - Pipeline by Encore Therapeutics Inc., H1 2015 34 Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H1 2015 35 Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H1 2015 36 Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2015 37 Post-Operative Pain - Pipeline by GW Pharmaceuticals plc, H1 2015 38 Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H1 2015 39 Post-Operative Pain - Pipeline by Immupharma Plc, H1 2015 40 Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H1 2015 41 Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 42 Post-Operative Pain - Pipeline by Medtronic, Inc., H1 2015 43 Post-Operative Pain - Pipeline by Ocular Therapeutix, Inc., H1 2015 44 Post-Operative Pain - Pipeline by Omeros Corporation, H1 2015 45 Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H1 2015 46 Post-Operative Pain - Pipeline by Orion Oyj, H1 2015 47 Post-Operative Pain - Pipeline by Pharmazz, Inc., H1 2015 48 Post-Operative Pain - Pipeline by PhytoHealth Corporation, H1 2015 49 Post-Operative Pain - Pipeline by Recro Pharma, Inc., H1 2015 50 Post-Operative Pain - Pipeline by Rottapharm SpA, H1 2015 51 Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 52 Post-Operative Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2015 53 Post-Operative Pain - Pipeline by Trevena, Inc., H1 2015 54 Post-Operative Pain - Pipeline by UMeWorld Limited, H1 2015 55 Assessment by Monotherapy Products, H1 2015 56 Assessment by Combination Products, H1 2015 57 Number of Products by Stage and Target, H1 2015 59 Number of Products by Stage and Mechanism of Action, H1 2015 61 Number of Products by Stage and Route of Administration, H1 2015 63 Number of Products by Stage and Molecule Type, H1 2015 65 Post-Operative Pain Therapeutics - Recent Pipeline Updates, H1 2015 126 Post-Operative Pain - Dormant Projects, H1 2015 153 Post-Operative Pain - Discontinued Products, H1 2015 155
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.